More on JNJ

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+7.7% Growth)
- Ratings (4.0 Score)
- Holders
- Dividends (2.9% Yield)
- Event Driven Deals
- FDA Archive

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (7/14/16 *Est.)
- Ex-Dividend (5/18/2016)
- Spin-Off (12/31/15 *Est)
- Conference (5/5/2016)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

JNJ Cash Flow Statement

Click line-items for a historical chart and %
CASH FLOW FROM OPERATING ACTIVITIES
Net earnings
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles 3.75B
Stock based compensation 874M
Deferred tax provision -270M
Accounts receivable allowances 18M
Changes in assets and liabilities, net of effects from acquisitions:
Increase in accounts receivable -433M
Increase in inventories -449M
Decrease in accounts payable and accrued liabilities -3M
Increase in other current and non-current assets 65M
Increase in other current and non-current liabilities 2.16B
NET CASH FLOWS FROM OPERATING ACTIVITIES 19.28B
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment -3.46B
Proceeds from the disposal of assets 3.46B
Acquisitions, net of cash acquired -954M
Purchases of investments -40.83B
Sales of investments 34.15B
Other -103M
NET CASH USED BY INVESTING ACTIVITIES -7.74B
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders -8.17B
Repurchase of common stock -5.29B
Proceeds from short-term debt 2.42B
Retirement of short-term debt -1.04B
Proceeds from long-term debt 75M
Retirement of long-term debt -68M
Proceeds from the exercise of stock options/ excess tax benefits
NET CASH USED BY FINANCING ACTIVITIES -10.85B
Effect of exchange rate changes on cash and cash equivalents -1.49B
Decrease in cash and cash equivalents -791M
Cash and Cash equivalents, beginning of period 14.52B
CASH AND CASH EQUIVALENTS, END OF PERIOD 13.73B
Acquisitions
Fair value of assets acquired 1.17B
Fair value of liabilities assumed and non-controlling interests -220M
Net cash paid for acquisitions 954M